Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.

Journal of cellular and molecular medicine - 1 Jan 2020

Atzori Maria Grazia, Ceci Claudia, Ruffini Federica, Trapani Mauro, Barbaccia Maria Luisa, Tentori Lucio, D'Atri Stefania, Lacal Pedro Miguel, Graziani Grazia

Abstract excerpt

The vascular endothelial growth factor receptor-1 (VEGFR-1) is a tyrosine kinase receptor frequently expressed in melanoma. Its activation by VEGF-A or placental growth factor (PlGF) promotes tumour cell survival, migration and invasiveness. Moreover, VEGFR-1 stimulation contributes to pathological angiogenesis and induces recruitment of tumour-associated macrophages. Since melanoma acquired resistance to BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Matrix
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Invasiveness

Share to Skin Neoplasms

Share to Vascular Endothelial Growth Factor A

Share to Vascular Endothelial Growth Factor Receptor-1

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 31758648
DOI: 10.1111/jcmm.14755
PMCID: PMC6933379

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.PMID 31758648Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Semantic proximity Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read ↗

A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

[Mechanisms of resistance to anti-BRAF treatments].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.